Analysts predict that Urogen Pharma (NASDAQ:URGN) will announce sales of $7.67 million for the current quarter, Zacks reports. Three analysts have provided estimates for Urogen Pharma’s earnings, with the highest sales estimate coming in at $8.00 million and the lowest estimate coming in at $7.50 million. The business is scheduled to report its next quarterly earnings results on Monday, November 13th.

On average, analysts expect that Urogen Pharma will report full-year sales of $7.67 million for the current financial year, with estimates ranging from $7.50 million to $8.00 million. For the next year, analysts expect that the company will post sales of $0.00 per share. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Urogen Pharma.

Several research analysts have weighed in on URGN shares. Oppenheimer Holdings, Inc. set a $32.00 price target on Urogen Pharma and gave the stock a “buy” rating in a research report on Monday, August 14th. Zacks Investment Research raised Urogen Pharma from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Wednesday, August 2nd. Jefferies Group LLC started coverage on Urogen Pharma in a research report on Tuesday, May 30th. They set a “buy” rating and a $27.00 price target on the stock. Raymond James Financial, Inc. started coverage on Urogen Pharma in a research report on Tuesday, May 30th. They set an “outperform” rating and a $25.00 price target on the stock. Finally, Cowen and Company started coverage on Urogen Pharma in a research report on Tuesday, May 30th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $26.00.

Several hedge funds have recently bought and sold shares of URGN. Alps Advisors Inc. acquired a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $195,000. LLBH Private Wealth Management LLC acquired a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $695,000. Spark Investment Management LLC acquired a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $856,000. Menora Mivtachim Holdings LTD. acquired a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $2,331,000. Finally, Wildcat Capital Management LLC acquired a new position in shares of Urogen Pharma during the 2nd quarter worth approximately $2,439,000. 36.06% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “$7.67 Million in Sales Expected for Urogen Pharma (URGN) This Quarter” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/09/17/7-67-million-in-sales-expected-for-urogen-pharma-urgn-this-quarter.html.

Shares of Urogen Pharma (URGN) traded down 0.09% during midday trading on Friday, reaching $32.69. The company’s stock had a trading volume of 62,385 shares. The company has a 50-day moving average price of $21.34 and a 200-day moving average price of $18.90. Urogen Pharma has a 12 month low of $13.01 and a 12 month high of $33.77. The firm’s market cap is $425.30 million.

About Urogen Pharma

Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.